Clinical Trial

A Study of ES104 in Patients With Metastatic Colorectal Cancer

Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 15, 2023 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal cancer who have failed systemic therapies.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05167448
Lead Sponsor Elpiscience (Suzhou) Biopharma, Ltd.
Conditions Metastatic Colorectal Cancer
Enrollment 58 participants
Start Date 2022-02-25
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-15